Drug administration controller

Abstract
A drug administration controller has a sensor that generates a sensor signal to a physiological measurement device, which measures a physiological parameter in response. A control output responsive to the physiological parameter or a metric derived from the physiological parameter causes a drug administration device to affect a treatment of a person, such as by initiating, pausing, halting or adjusting a dosage of drugs administered to the person.
Description
BACKGROUND

Physiological measurement systems employed in healthcare often feature visual and audible alarm mechanisms that alert a caregiver when a patient's vital signs are outside of predetermined limits. For example, a pulse oximeter, which measures the oxygen saturation level of arterial blood, indicates oxygen supply. A typical pulse oximetry system has a sensor that provides a signal output to a pulse oximeter monitor. The sensor has an emitter configured with both red and infrared LEDs that project light through a fleshy medium to a detector so as to determine the ratio of oxygenated and deoxygenated hemoglobin light absorption. The monitor has a signal processor, a display and an alarm. The signal processor inputs the conditioned and digitized sensor signal and calculates oxygen saturation (SpO2) along with pulse rate (PR), as is well-known in the art. The display provides a numerical readout of a patient's oxygen saturation and pulse rate. The alarm provides an audible indication when oxygen saturation or pulse rate are outside of predetermined limits.


Another pulse oximetry parameter is perfusion index (PI). PI is a measure of perfusion at the pulse oximetry sensor site comparing the pulsatile (AC) signal to the non-pulsatile (DC) signal, expressed as a percentage ratio. An example is the PI Delta Alarm™ feature of the Radical 7™ Pulse CO-Oximeter™ available from Masimo Corporation, Irvine, Calif., which alerts clinicians to specified changes in PI. In particular, PI Delta indicates if PI at a monitored site decreases by a specific level (delta) over a specified window of time, with both variables selectable by the user within predetermined ranges.


Tracking a series of desaturations over time is one metric that is derived from SpO2 that is well-known in the art. See, e.g., Farney, Robert J., Jensen, Robert L.; Ear Oximetry to Detect Apnea and Differentiate Rapid Eye Movement (REM) and Non-REM (NREM) Sleep: Screening for the Sleep Apnea Syndrome; Chest; April 1986; pages 533-539, incorporated by reference herein. Traditional high and low SpO2 alarm limits alert clinicians to saturation levels that exceed user selected thresholds, and these thresholds are typically established at a considerable change from the patients' baseline saturation level. However, in select patient populations, substantial desaturation events that exceed a typical low alarm limit threshold may be preceded by a cycle of transient desaturations over a limited timeframe. The ability to alert clinicians to a cycle of these smaller desaturations provides an earlier indication of a potential significant decline in the patient's status and the need for more focused monitoring and/or a change in treatment. An example is the Desat Index Alarm™ feature of the Radical 7™, mentioned above, which enables clinicians to detect an increasing quantity of smaller desaturations that may precede declining respiratory status. Desat Index is a measure responsive to patients that experience a specific number of desaturations beyond a defined level from the patient's baseline saturation over a specific window of time, with each of these variables selectable by the user within predetermined ranges.


A physiological parameter that can be measured in addition to, or in lieu of, SpO2 is respiration rate (RR). A respiration rate monitor utilizes a body sound sensor with piezoelectric membranes particularly suited for the capture of acoustic waves and the conversion thereof into electric signals. To detect body sound, the piezoelectric membranes are used as mechano-electric transducers that are temporarily polarized when subject to a physical force, such as when subjected to the mechanical stress caused by the acoustic waves coming from the inside of a patient's body. The body sound sensor is typically attached to the suprasternal notch or at the lateral neck near the pharynx so as to detect tracheal sounds. A sound sensor is described in U.S. Pat. No. 6,661,161 entitled Piezoelectric Biological Sound Monitor With Printed Circuit Board, incorporated by reference herein. A respiration rate monitor is described in U.S. patent application Ser. No. 11/547,570 entitled Non-Invasive Monitoring of Respiratory Rate, Heart Rate and Apnea, incorporated by reference herein.


SUMMARY

Conventional patient monitors give insufficient advance warning of deteriorating patient health or the onset of a potentially serious physiological condition. Advantageously, a drug administration controller is responsive to one or more physiological parameters in addition to, or in lieu of, SpO2 and PR, such as carboxyhemoglobin (HbCO), methemoglobin (HbMet), perfusion index (PI) and respiration rate (RR), to name a few. Further, a drug administration controller is advantageously responsive not only to preset parameter limits but also to various metrics derived from measured physiological parameters, such as trends, patterns and variability, alone or in combination, to name a few. As such, a drug administration controller is adapted to pausing or otherwise affecting drug administration based upon one or more physiological parameters and one or more metrics. Parameter variability is described with respect to PI in U.S. patent application Ser. No. 11/094,813 entitled Physiological Assessment System, incorporated by reference herein.


As an example, a drug administration controller may be responsive to changes in HbMet. Gaseous nitric oxide (NO) is increasingly recognized as an effective bacteriostatic or bacteriocidal agent. NO, however, can toxically increase HbMet.


A drug administration controller may be responsive to changes in perfusion index, such as measured by PI Delta, described above. PI may change dramatically in response to sympathetic changes in vasoconstriction or vasodilation of peripheral vessels caused by anesthesia or pain. For example, painful stimulus causes a significant decline of perfusion index.


As another example, a drug administration controller may be responsive to a cycle of transient desaturations over a limited timeframe, such as indicated by Desat Index, described above. Patients receiving pain medication may be predisposed to respiratory depression. If the patient has an underlying respiratory condition, pain medication may cause the patient to spiral into a cascade of cyclic desaturations, which initially are mild but may worsen quickly, leading to respiratory depression and even arrest.


As a further example, a drug administration controller may be responsive to respiration rate (RR) monitoring, as described above. RR provides an accurate marker for indicating acute respiratory dysfunction. For example, during conscious sedation, there is a risk of respiratory depression, and changes in RR typically provide an earlier warning than does pulse oximetry alone.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a general block diagram of a drug administration controller;



FIGS. 2A-C are illustrations of drug infusion controller embodiments;



FIGS. 3A-C are illustrations of medical gas controller embodiments;



FIG. 4 is a general block diagram of a parameter processor embodiment; and



FIG. 5 is a detailed block diagram of a parameter processor embodiment.





DETAILED DESCRIPTION


FIG. 1 illustrates a drug administration controller 100 having one or more sensors 106 generating sensor signals 107 in response to physiological states of a living being, such as a patient 1. One or more physiological measurement devices 108 generate physiological parameter measurements 103 in response to the sensor Signals 107. A multiple parameter processor 101 processes the parameter measurements 103 alone or in combination and generates monitor or control outputs 102, or both, in response. In an open-loop configuration, one or more monitor outputs 102 are observed by a caregiver 2, who administers drugs or alters drug doses in response. Alternatively, or in addition to, the caregiver 2 initiates, pauses, halts or adjusts the settings of a drug administration device 104. In a closed-loop configuration, a drug administration device 104 is responsive to one or more control outputs 102 so as to affect the treatment of the patient 1, including initiating, pausing, halting or adjusting the dosage of administered drugs.


As shown in FIG. 1, the drug administration device may be, as examples, a drug infusion device or a medical gas inhalation device. Closed loop drug infusion control is described in U.S. patent application Ser. No. 11/075,389, entitled Physiological Parameter Controller, incorporated by reference herein. Closed loop respirator control is described in U.S. Pat. App. No. 60/729,470 entitled Multi-Channel Pulse Oximetry Ventilator Control, incorporated by reference herein.


Also shown in FIG. 1, sensors 106 may include an optical sensor attached to a tissue site, such as a fingertip, for measuring one or more blood parameters. Sensors 106 may also include blood pressure cuffs, ECG or EEG electrodes, CO2 measuring capnography sensors and temperature sensors to name but a few. Corresponding physiological measurement devices 108 responsive to these sensors 106 may include blood parameter monitors, blood pressure monitors, capnometers, ECG and EEG monitors, as a few examples.


In one embodiment, sensors 106 include a pulse oximetry sensor, such as described in U.S. Pat. No. 5,782,757 entitled Low Noise Optical Probes and physiological measurement devices 108 include a pulse oximeter, such as described in U.S. Pat. No. 5,632,272 entitled Signal Processing Apparatus, both assigned to Masimo Corporation, Irvine, Calif. and both incorporated by reference herein. In another embodiment, sensors 106 and measurement devices 108 include a multiple wavelength sensor and a corresponding noninvasive blood parameter monitor, such as the RAD-57™ and Radical-7™ for measuring SpO2, CO, HbMet, pulse rate, perfusion index and signal quality. The RAD-57 and Radical-7 are available from Masimo Corporation, Irvine, Calif. In other embodiments, sensors 106 also include any of LNOP® adhesive or reusable sensors, SofTouch™ sensors, Hi-Fi Trauma™ or Blue™ sensor all available from Masimo Corporation, Irvine, Calif. Further, measurement devices 108 also include any of Radical®, SatShare™, Rad-9™, Rad-5™, Rad-5v™ or PPO+™ Masimo SET® pulse oximeters all available from Masimo Corporation, Irvine, Calif.


In a particular embodiment, the control or monitor outputs 102 or both are responsive to a Desat Index or a PI Delta or both, as described above. In another particular embodiment, one or more of the measurement devices 108, the parameter processor 101 and the drug administrative device 104 are incorporated within a single unit. For example, the devices may be incorporated within a single housing, or the devices may be separately housed but physically and proximately connected.


Although sensors 106 are described above with respect to noninvasive technologies, sensors 106 may be invasive or noninvasive. Invasive measurements may require a person to prepare a blood or tissue sample, which is then processed by a physiological measurement device.



FIG. 2A illustrates a drug infusion controller embodiment 200 comprising a drug-infusion pump 204, an optical sensor 206 attached to a patient 1 and a noninvasive blood parameter monitor 208. The optical sensor 206 provides a sensor Signal via a sensor cable 207 to the blood parameter monitor 208. The blood parameter monitor 208 generates blood parameter measurements and processes those parameters to generate monitor and control outputs 203 (FIG. 1), as described in further detail with respect to FIGS. 4-5, below. In particular, the blood parameter monitor 208 generates control signals via a control cable 202 to the drug-infusion pump 204, and the drug-infusion pump 204 administers drugs to the patient 1 via an IV 209, accordingly.


In one embodiment, the administered drug is a nitrate, such as sodium nitroprusside, and the blood parameter monitored is HbMet. In a particular embodiment, the blood parameter monitor 208 provides a control output according to one or more entries in TABLE 1. In another particular embodiment, the blood parameter monitor 208 provides a control output according to one or more entries in TABLE 2. In yet another embodiment, a blood parameter monitor 208 confirms that the measurement of HbMet is accurate, such as by checking a signal quality parameter or by having multiple sensors 206 on the patient 1.



FIG. 2B illustrates another drug infusion controller embodiment 201 comprising an optical sensor 206 and a combination blood-parameter monitor/drug infusion pump 205. In an embodiment, the drug infusion controller 200, 201 provides a visual display or audible alarm indicating various degrees of patient condition, such as green, yellow and red indicators or intermittent and low volume, medium volume and high volume tones.









TABLE 1







Rule Based Monitor Outputs










RULE
OUTPUT







If HbMet > limit threshold
disable pump; trigger alarm



if HbMet > trend threshold
disable pump; trigger alarm

















TABLE 2







Rule-Based Monitor Outputs










RULE
OUTPUT







If HbMet > limit threshold
disable pump; trigger alarm



if HbMet > trend threshold
reduce dosage; activate caution




indicator










Another embodiment involves patient controlled analgesia (PCA), i.e. the administered drug is an analgesia, and administration of the drug is controlled by the patient according to perceived pain levels. Analgesia administration, however, is paused in response to one or more blood parameters and corresponding metrics. In one embodiment, the blood parameter monitored is SpO2 and the blood parameter monitor 208 provides a control output responsive to Desat Index. In a particular embodiment, PCA is paused or disabled according to TABLE 3.









TABLE 3







Rule Based PCA Control Outputs










RULE
OUTPUT







If Desat Index > index limit
pause PCA for predetermined




period; activate alarm










In another embodiment, the blood parameter monitor 208 provides a control output responsive to a PI indication of pain. In this manner, the administration of anesthesia is controlled according to the patient's perceived pain level. In a particular embodiment, PCA is paused or enabled according to one or more entries of TABLE 4, where a falling PI results in a negative PI Delta relative to an established baseline.









TABLE 4







Rule Based PCA Control Outputs










RULE
OUTPUT







If PI Delta < delta limit
enable PCA; activate caution




indicator



If PI Delta < delta limit
disable PCA











FIG. 2C illustrates yet another drug infusion controller embodiment 211 having a piezoelectric sensor 216 and a combination blood-parameter/piezoelectric sound monitor/drug infusion pump 218. A piezoelectric sensor 216 is attached to a patient's body 1 so as to detect tracheal sounds. The corresponding sensor signal is transmitted to the sound monitor 218 via a sensor cable 217. The sound monitor/pump 218 generates biological sound measurements such as respiration rate (RR) and processes the measurements to generate control outputs. In a particular embodiment, the monitor/pump 218 provides a control output according to one or more entries of TABLE 5.









TABLE 5







Rule Based Monitor Outputs










RULE
OUTPUT







If RR trend < trend threshold
reduce dosage; activate caution




indicator



If RR < limit threshold
disable pump; trigger alarm











FIG. 3A illustrates a medical gas controller embodiment 300 comprising a ventilator 304 adapted to supply both oxygen and a medical gas, an optical sensor 306 attached to a patient 1, and a noninvasive blood parameter monitor 308. The optical sensor 306 provides a sensor signal via a sensor cable 307 to the blood parameter monitor 308. The blood parameter monitor 308 generates blood parameter measurements and processes those parameters to generate monitor and control outputs, as described with respect to FIGS. 4-5, below. In particular, the blood parameter monitor 308 generates control signals via a control cable 302 to the ventilator 304, and the ventilator 304 administers a medical gas to the patient 1 via a breathing apparatus 309 accordingly. FIG. 3B illustrates another medical gas controller embodiment 301 comprising an optical sensor 306 and a combination blood-parameter monitor/ventilator 305.


In one embodiment, the administered medical gas is a NO, and the blood parameter monitored is HbMet. In a particular embodiment, the blood parameter monitor 308 provides a control output according to one or more entries of TABLE 6. In another particular embodiment, the blood parameter monitor 308 provides a control output according to one or more entries of TABLE 7. In yet another embodiment, a blood parameter monitor 308 confirms that the measurement of HbMet is accurate, such as by checking a signal quality parameter or by having multiple sensors 306 on the patient 1. In a further embodiment, the administered medical gas is CO, and the blood parameter monitored is HbCO.









TABLE 6







Rule Based Monitor Outputs










RULE
OUTPUT







If HbMet trend > trend threshold
halt NO flow; trigger alarm



If HbMet > limit threshold
halt NO flow; trigger alarm

















TABLE 7







Rule Based Monitor Outputs








RULE
OUTPUT





If HbMet trend > trend threshold
reduce NO flow; activate caution



indicator


If HbMet > limit threshold
halt NO flow; trigger alarm










FIG. 3C illustrates yet another medical gas controller embodiment 311 comprising a piezoelectric sound sensor 316 and a combination blood parameter/piezoelectric sound monitor/ventilator 315. The sound sensor 316 is attached to a patient's body 1 so as to detect tracheal sounds and provides a sensor signal via a sensor cable 317 to the sound monitor 315. The sound monitor/ventilator 315 generates biological sound measurements such as respiration rate (RR) and provides control outputs responsive to RR. In a particular embodiment, the monitor/ventilator 315 provides a control output according to one or more entries of TABLE 8.









TABLE 8







Rule Based Monitor Outputs








RULE
OUTPUT





If RR trend < trend threshold
reduce medical gas flow;



activate caution indicator


If RR limit < limit threshold
halt medical gas flow; trigger alarm










FIG. 4 illustrates a parameter processor 101, which may comprise an expert system, a neural-network or a logic circuit as examples. The parameter processor 101 has as inputs 103 one or more parameters from one or more physiological measurement devices 108 (FIG. 1). Noninvasive parameters may include oxygen saturation (SpO2), pulse rate, perfusion index, HbCO, HbMet and other Hb species, and data confidence indicators, such as derived from a pulse oximeter or a Pulse Co-Oximeter™ (Masimo Corporation) to name a few. Invasive parameters may include lactate, glucose or other blood constituent measurements. Capnography parameters may include, for example, end tidal carbon dioxide (ETCO2) and respiration rate. Other measurement parameters that can be input to the parameter processor 101 may include ECG, EEG, blood pressure and temperature to name a few. All of these parameters may indicate real-time measurements or historical data, such as would indicate a measurement trend. Pulse oximetry signal quality and data confidence indicators are described in U.S. Pat. No. 6,684,090 entitled Pulse Oximetry Data Confidence Indicator, assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.


As shown in FIG. 4, monitor outputs 102 may be alarms. wellness indicators, controls and diagnostics. Alarms may be used to alert medical personnel to a potential urgent or emergency medical condition in a patient under their care. Wellness indicators may be used to inform medical personnel as to patient condition stability or instability, such as a less urgent but potentially deteriorating medical state or condition. Controls may be used to affect the operation of a medical treatment device or other medical-related equipment. Diagnostics may be messages or other indicators used to assist medical personnel in diagnosing or treating a patient condition.


User I/O 60, external devices 70 and wireless communication 80 also interface with the parameter processor 101 and provide communications to the outside world. User I/O 60 allows manual data entry and control. For example, a menu-driven operator display may be provided to allow entry of predetermined alarm thresholds. External devices 70 may include PCs and network interfaces to name a few.



FIG. 5 illustrates one embodiment of a parameter processor 101 having a pre-processor 510, a metric analyzer 520, a post-processor 530 and a controller 540. The pre-processor 510 has inputs 103 that may be real-time physiological parameter measurements, historical physiological parameter measurements, signal quality measures or any combination of the above. The pre-processor 510 generates metrics 512 that may include historical or real-time parameter trends, detected parameter patterns, parameter variability measures and signal quality indicators to name a few. As examples, trend metrics may indicate if a physiological parameter is increasing or decreasing at a certain rate over a certain time, pattern metrics may indicate if a parameter oscillates within a particular frequency range or over a particular time period, variability metrics may indicate the extent of parameter stability.


As shown in FIG. 5, the metric analyzer 520 is configured to provide test results 522 to the post-processor based upon various rules applied to the metrics 512 in view of various thresholds 524. As an example, the metric analyzer 520 may output an alarm trigger 522 to the post-processor 530 when a parameter measurement 103 increases faster than a predetermined rate. This may be expressed by a rule that states “if trend metric exceeds trend threshold then trigger alarm.”


Also shown in FIG. 5, the post processor 530 inputs test results 522 and generates outputs 102 including alarms, wellness indictors, controls and diagnostics. Alarms may be, for example, audible or visual alerts warning of critical conditions that need immediate attention. Wellness indicators may be audible or visual cues, such as an intermittent, low-volume tone or a red/yellow/green light indicating a patient with a stable or unstable physiological condition. Controls may be electrical or electronic, wired or wireless or mechanical outputs, to name a few, capable of interfacing with and affecting another device. As examples, controls 102 may interface with drug-infusion equipment or medical gas ventilation equipment, as described with respect to FIGS. 2A-C and 3A-C, above.


Further shown in FIG. 5, the controller 540 interfaces with I/O 109, as described with respect to FIG. 4, above. In one embodiment, the I/O 109 provides predetermined thresholds, which the controller 540 transmits to the metric analyzer 520. The controller 540 may also define metrics 514 for the pre-processor 510 and define outputs 534 for the post-processor 530.


A drug administration controller has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in art will appreciate many variations and modifications.

Claims
  • 1. A drug administration controller comprising: at least one sensor that generates at least one sensor signal in response to a physiological state of a living being that is being monitored;at least one physiological measurement device that generates physiological parameter measurements of at least one physiological parameter in response to the at least one sensor signal;a processor that generates one or more control outputs in response to the physiological parameter measurements, wherein the physiological parameter measurements include a measure of a number of times, which is greater than a predetermined threshold, that cyclical desaturations occur in the living being that is being monitored over a given timeframe; anda drug administration device responsive to the one or more control outputs that are responsive to the physiological parameter measurements including the measure of the number of times, which is greater than a predetermined threshold, that cyclical desaturations occur in the living being that is being monitored over a given timeframe so as to affect a treatment of the living being that is being monitored, including at least one of initiating, pausing, halting, or adjusting a dosage of drugs administered to the living being that is being monitored.
  • 2. The drug administration controller according to claim 1, wherein the drug administration device includes at least one of: a drug infusion device or a medical gas inhalation device.
  • 3. The drug administration controller according to claim 2, wherein the at least one sensor comprises: an optical sensor attached to a tissue site so as to measure at least one blood parameter; anda sound sensor attached proximate to a neck site so as to measure respiration rate.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of U.S. patent application Ser. No. 13/475,136, filed May 18, 2012, entitled Drug Administration Controller, which is a continuation of U.S. patent application Ser. No. 11/654,904, filed Jan. 17, 2007, entitled Drug Administration Controller, which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 60/759,673, filed Jan. 17, 2006, entitled Drug Administration Controller, and Ser. No. 60/764,946, filed Feb. 2, 2006, entitled Drug Administration Controller, all of which are incorporated by reference herein in their entireties.

US Referenced Citations (684)
Number Name Date Kind
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5163438 Gordon et al. Nov 1992 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5685299 Diab et al. Nov 1997 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kianl Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6745060 Diab et al. Jun 2004 B2
6760607 Al-All Jul 2004 B2
6760608 Lynn Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6792300 Diab et al. Sep 2004 B1
6807965 Hickle Oct 2004 B1
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6898452 Al-Ali et al. May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7067893 Mills et al. Jun 2006 B2
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
7132641 Schulz et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7526328 Diab et al. Apr 2009 B2
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7618375 Flaherty Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
7668579 Lynn Feb 2010 B2
D614305 Al-Ali et al. Apr 2010 S
RE41317 Parker May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
20030000522 Lynn Jan 2003 A1
20050277819 Kiani et al. Dec 2005 A1
20070282478 Al-Ali et al. Dec 2007 A1
20080030468 Ali et al. Feb 2008 A1
20090247984 Lamego et al. Oct 2009 A1
20090275813 Davis Nov 2009 A1
20090275844 Al-Ali Nov 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20110082711 Poeze et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110213212 Al-Ali Sep 2011 A1
20110230733 Al-Ali Sep 2011 A1
20110237969 Eckerbom et al. Sep 2011 A1
20110288383 Diab Nov 2011 A1
20110301444 Al-Ali Dec 2011 A1
20120041316 Al-Ali et al. Feb 2012 A1
20120046557 Kiani Feb 2012 A1
20120059267 Lamego et al. Mar 2012 A1
20120088984 Al-Ali et al. Apr 2012 A1
20120165629 Merritt et al. Jun 2012 A1
20120179006 Jansen et al. Jul 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120296178 Lamego et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20120330112 Lamego et al. Dec 2012 A1
20130006076 McHale Jan 2013 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130046204 Lamego et al. Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130190581 Al-Ali et al. Jul 2013 A1
20130211214 Olsen Aug 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130262730 Al-Ali et al. Oct 2013 A1
20130267804 Al-Ali Oct 2013 A1
20130274572 Al-Ali et al. Oct 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130296713 Al-Ali et al. Nov 2013 A1
20130317370 Dalvi et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331660 Al-Ali et al. Dec 2013 A1
20130331670 Kiani Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140034353 Al-Ali et al. Feb 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140066783 Kiani et al. Mar 2014 A1
20140077956 Sampath et al. Mar 2014 A1
20140081100 Muhsin et al. Mar 2014 A1
20140081175 Telfort Mar 2014 A1
20140094667 Schurman et al. Apr 2014 A1
20140100434 Diab et al. Apr 2014 A1
20140114199 Lamego et al. Apr 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140121483 Kiani May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140129702 Lamego et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140142401 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140194766 Al-Ali et al. Jul 2014 A1
20140206963 Al-Ali Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140275881 Lamego et al. Sep 2014 A1
20140276115 Dalvi et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140303520 Telfort et al. Oct 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140330099 Al-Ali et al. Nov 2014 A1
20140336481 Shakespeare et al. Nov 2014 A1
20140357966 Al-Ali et al. Dec 2014 A1
20140371548 Al-Ali et al. Dec 2014 A1
20140371632 Al-Ali et al. Dec 2014 A1
20140378784 Kiani et al. Dec 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150012231 Poeze et al. Jan 2015 A1
20150018650 Al-Ali et al. Jan 2015 A1
20150025406 Al-Ali Jan 2015 A1
20150032029 Al-Ali et al. Jan 2015 A1
20150038859 Dalvi et al. Feb 2015 A1
20150045637 Dalvi Feb 2015 A1
20150045685 Al-Ali et al. Feb 2015 A1
20150051462 Olsen Feb 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150087936 Al-Ali et al. Mar 2015 A1
20150094546 Al-Ali Apr 2015 A1
20150097701 Al-Ali et al. Apr 2015 A1
20150099324 Wojtczuk et al. Apr 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20150099951 Al-Ali et al. Apr 2015 A1
20150099955 Al-Ali et al. Apr 2015 A1
20150101844 Al-Ali et al. Apr 2015 A1
20150106121 Muhsin et al. Apr 2015 A1
20150112151 Muhsin et al. Apr 2015 A1
20150116076 Al-Ali et al. Apr 2015 A1
20150126830 Schurman et al. May 2015 A1
20150133755 Smith et al. May 2015 A1
20150140863 Al-Ali et al. May 2015 A1
20150141781 Weber et al. May 2015 A1
20150165312 Kiani Jun 2015 A1
20150196237 Lamego Jul 2015 A1
20150201874 Diab Jul 2015 A1
20150208966 Al-Ali Jul 2015 A1
20150216459 Al-Ali et al. Aug 2015 A1
20150230755 Al-Ali et al. Aug 2015 A1
20150238722 Al-Ali Aug 2015 A1
20150245773 Lamego et al. Sep 2015 A1
20150245793 Al-Ali et al. Sep 2015 A1
20150245794 Al-Ali Sep 2015 A1
20150257689 Al-Ali et al. Sep 2015 A1
20150272514 Kiani et al. Oct 2015 A1
20150351697 Weber et al. Dec 2015 A1
20150351704 Kiani et al. Dec 2015 A1
20150359429 Al-Ali et al. Dec 2015 A1
20150366472 Kiani Dec 2015 A1
20150366507 Blank Dec 2015 A1
20150374298 Al-Ali et al. Dec 2015 A1
20150380875 Coverston et al. Dec 2015 A1
20160000362 Diab et al. Jan 2016 A1
20160007930 Weber et al. Jan 2016 A1
20160029932 Al-Ali Feb 2016 A1
20160029933 Al-Ali et al. Feb 2016 A1
20160045118 Kiani Feb 2016 A1
20160051205 Al-Ali et al. Feb 2016 A1
20160058338 Schurman et al. Mar 2016 A1
20160058347 Reichgott et al. Mar 2016 A1
20160066823 Al-Ali et al. Mar 2016 A1
20160066824 Al-Ali et al. Mar 2016 A1
20160066879 Telfort et al. Mar 2016 A1
20160072429 Kiani et al. Mar 2016 A1
20160073967 Lamego et al. Mar 2016 A1
20160081552 Wojtczuk et al. Mar 2016 A1
20160095543 Telfort et al. Apr 2016 A1
20160095548 Al-Ali et al. Apr 2016 A1
20160103598 Al-Ali et al. Apr 2016 A1
20160113527 Al-Ali et al. Apr 2016 A1
20160143548 Al-Ali May 2016 A1
Non-Patent Literature Citations (2)
Entry
US 8,845,543 B2, 09/2014, Diab et al. (withdrawn)
Farney, Robert J., Jensen, Robert L.; Ear Oximetry to Detect Apnea and Differentiate Rapid Eye Movement (REM) and Non-Rem (NREM) Sleep: Screening for the Sleep Apnea Syndrome ; Chest; Apr. 1986; pp. 533-539.
Related Publications (1)
Number Date Country
20160287786 A1 Oct 2016 US
Provisional Applications (2)
Number Date Country
60759673 Jan 2006 US
60764946 Feb 2006 US
Divisions (1)
Number Date Country
Parent 13475136 May 2012 US
Child 15094100 US
Continuations (1)
Number Date Country
Parent 11654904 Jan 2007 US
Child 13475136 US